Cytokinetics, Incorporated Company Profile (NASDAQ:CYTK)

Cytokinetics, Incorporated trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Incorporated (NASDAQ:CYTK) released its quarterly earnings results on Thursday, February, 16th. The company reported $0.16 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.55. The business earned $33.14 million during the quarter, compared to analyst estimates of $14.10 million. Cytokinetics, Incorporated had a net margin of 1.53% and a return on equity of 1.94%. View Cytokinetics, Incorporated's Earnings History.

9 analysts have issued 1 year price targets for Cytokinetics, Incorporated's stock. Their forecasts range from $15.00 to $25.00. On average, they anticipate Cytokinetics, Incorporated's stock price to reach $21.11 in the next twelve months. View Analyst Ratings for Cytokinetics, Incorporated.

Here are some recent quotes from research analysts about Cytokinetics, Incorporated stock:

• 1. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (7/17/2017)
• 2. Rodman & Renshaw analysts commented, "Our price target is based on our clinical net present value (NPV) model, which is currently driven by omecamtiv mecarbil ($19.77/share) and modest contributions from tirasemtiv ($4.26/share) and CK-107 ($1.05/share). We believe this method is appropriate in capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including chance of success, peak sales estimates, and year of commercial launch. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (3/23/2017)
• 3. HC Wainwright analysts commented, "We have adjusted our 2017 estimates downward accordingly. The company had a net loss of $4.3M in 4Q16, or ($0.81) per share based on shares adjusted for the 1-for-10 reverse split effective on February 27. 2016. The loss was lower than our estimate of $4.9M due to improved expense management. For the fiscal year 2016, TearLab had $28M in revenue, representing 11% growth over that of 2015, and $19.9M in net loss. In our view, the softened growth rate in the Flex program and in international markets could continue in 2017. Therefore, we currently project a conservative low single-digit growth in revenue in 2017. Our valuation of the company has decreased from $140M to $105M. Excluding debt, our estimated market value of the firm is $79M. Assuming 6.5M shares outstanding at the end of 2017, we project a 12-month price target of $12 per share. Our previous price target was $2 before the reverse split. Importantly, TearLab has begun a process to explore strategic alternatives, which does not preclude a sale of the company." (3/13/2017)
• 4. Cantor Fitzgerald analysts commented, "We rate CYTK Overweight and maintain our $21 price target. Cytokinetics has three late-stage programs with quality partners that should begin to read data out in the next year. The company is targeting substantial unmet medical needs and has been methodically pursuing clinical development for its candidates. We think the major overhangs have receded from the shares and that, with near-term data on the horizon, the shares have opportunity for valuation expansion." (2/17/2017)
• 5. FBR & Co analysts commented, "On February 16, CYTK announced 4Q16 results dominated by the achievement of significant milestones in its cardiac muscle-directed clinical program (omecamtiv mecarbil, or OM) and important milestones in its skeletal muscle program (tirasemtiv and CK-2127107), which we think will continue to emerge in value in 2017. One highlight was the initiation of the GALACTIC-HF Phase III outcomes trial with OM by its partner Amgen. Another 4Q highlight was enrollment of the first patient in the open-label VIGOR-ALS trial with tirasemtiv, designed to assess the safety of tirasemtiv, which would be directed for long-term daily use in patients with amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). We think CYTK's valuation is disconnected from the value of the more than $1B in milestone payments that CYTK could realize from its partners. Therefore, we reiterate our Outperform rating." (2/17/2017)

Some companies that are related to Cytokinetics, Incorporated include Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Clinigen Group PLC (CLIN), Xencor (XNCR), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), Synergy Pharmaceuticals (SGYP), Omeros Corporation (OMER), Aduro Biotech (ADRO), Achaogen (AKAO), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), PTC Therapeutics (PTCT), Five Prime Therapeutics (FPRX) and NeuroDerm (NDRM).

Cytokinetics, Incorporated's management team includes the folowing people:

• Leonard Patrick Gage Ph.D., Independent Chairman of the Board
• Robert I. Blum, President, Chief Executive Officer, Director
• Ching Jaw, Chief Financial Officer, Senior Vice President
• Sharon A. Barbari, Executive Vice President - Finance
• Fady I. Malik M.D. Ph.D., Executive Vice President - Research and Development
• Peter S. Roddy, Senior Vice President, Chief Accounting Officer
• David W. Cragg, Senior Vice President - Human Resources
• Bonnie A. Charpentier Ph.D., Senior Vice President - Regulatory Affairs and Compliance
• Bradley Paul Morgan Ph.D., Senior Vice President - Research and Non-Clinical Development
• Elisabeth Schnieders Ph.D., Senior Vice President - Business Development

Cytokinetics, Incorporated's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (6.40%), Fox Run Management L.L.C. (0.08%), Bank of Montreal Can (0.05%), Capstone Asset Management Co. (0.04%), Louisiana State Employees Retirement System (0.04%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Cytokinetics, Incorporated stock include Fady Ibraham Malik, L Patrick Gage and Robert I Blum. View Institutional Ownership Trends for Cytokinetics, Incorporated.

Cytokinetics, Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C., Capstone Asset Management Co., Louisiana State Employees Retirement System, Bank of Montreal Can and State of Alaska Department of Revenue. View Insider Buying and Selling for Cytokinetics, Incorporated.

Shares of Cytokinetics, Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cytokinetics, Incorporated stock can currently be purchased for approximately $14.50.